<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Yongdong Zhao, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fatma Dedeoglu, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Sundel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Suzanne C Li, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3693942141"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO) is a chronic, sterile, inflammatory disorder in children that primarily affects the bones and can cause bone destruction if untreated [<a href="#rid1">1-4</a>]. CNO can be sporadic or occur as part of a monogenic autoinflammatory condition such as deficiency of interleukin (IL) 1 receptor antagonist (DIRA) or Majeed syndrome. SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteitis) is an adult disease with similar features to CNO. It is not clear if they are different diseases or represent the same condition in a spectrum with some age-specific factors [<a href="#rid5">5</a>].</p><p>The clinical features, diagnosis, management, and prognosis of sporadic CNO/CRMO are reviewed here. SAPHO is discussed separately, as are the monogenic autoinflammatory diseases. (See  <a class="medical medical_review" href="/z/d/html/99510.html" rel="external">"SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>.)</p><p>Osteomyelitis due to infection is also discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6063.html" rel="external">"Hematogenous osteomyelitis in children: Epidemiology, pathogenesis, and microbiology"</a> and  <a class="medical medical_review" href="/z/d/html/6064.html" rel="external">"Hematogenous osteomyelitis in children: Clinical features and complications"</a> and  <a class="medical medical_review" href="/z/d/html/6067.html" rel="external">"Hematogenous osteomyelitis in children: Evaluation and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5958.html" rel="external">"Hematogenous osteomyelitis in children: Management"</a>.)</p><p class="headingAnchor" id="H146786036"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>While both terms, "chronic nonbacterial osteomyelitis" (CNO) and "chronic recurrent multifocal osteomyelitis" (CRMO), are used to describe this disorder, CRMO is often perceived as the more severe form, and CNO is used as the general term for the condition.</p><p class="headingAnchor" id="H3084934781"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>CNO is a rare disease (MIM #259680, ORPHA:324964), with slightly over 500 existing patients reported worldwide [<a href="#rid6">6</a>]. CNO is likely underdiagnosed and underreported due to lack of awareness of CNO in the general population and medical communities, absence of validated diagnostic criteria, and difficulty of collecting data in countries without national registries [<a href="#rid7">7</a>]. CNO is reported in all races, ethnicities, and geographic areas [<a href="#rid8">8</a>]. Reported incidence is higher in Western countries, especially in Europe. As an example, a nationwide survey conducted among treating clinicians through pediatric hospitals in Germany between 2006 and 2008 estimated the annual incidence of CNO at 1 in 250,000 [<a href="#rid9">9</a>]. However, this higher reported incidence may just reflect higher rates of diagnosis in such regions.</p><p>CNO can affect children of all ages, with a peak onset between 7 and 12 years [<a href="#rid9">9,10</a>]. There is female predominance, with a female-to-male ratio ranging from 1.5:1 to 4:1 in different series [<a href="#rid9">9-14</a>]. This ratio is in contrast to infectious conditions, which are more common in males. Even though CNO is seen in children of all ages, disease onset younger than age two years should trigger an investigation of a monogenic form of autoinflammatory conditions such as Majeed syndrome or deficiency of interleukin (IL) 1 receptor antagonist (DIRA). (See  <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a> and <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H3457806453"><span class="h1">GENETICS AND PATHOGENESIS</span><span class="headingEndMark"> — </span>The exact pathogenesis of CNO/CRMO is unknown. Both genetic and environmental factors are thought to contribute to the underlying inflammation.</p><p class="headingAnchor" id="H922306794"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>The underlying molecular causes of CNO are not fully understood. Several monogenic autoinflammatory disorders causing sterile bone inflammation have been reported in humans and in animals [<a href="#rid15">15-18</a>], and sporadic CNO shares many clinical features with some monogenic autoinflammatory conditions [<a href="#rid19">19</a>]. However, in multiple studies, no single gene defects were identified as important contributing factors to the pathogenesis of CNO [<a href="#rid20">20-22</a>].</p><p>Genetic predisposition in a polygenic pattern is more likely in sporadic forms of CNO, especially when the bone inflammation is associated with other polygenic diseases such as inflammatory bowel disease (IBD) [<a href="#rid23">23</a>] and psoriasis. In addition, polygenic inheritance best explains the sibling and parent/child pairs, as well as the increased prevalence of associated conditions in other family members [<a href="#rid10">10</a>]<em>. </em>Human leukocyte antigen (HLA) B27 was reported as more common in CNO patients than the general population in two cohorts (21 versus 8 percent) [<a href="#rid12">12,13</a>], while no difference was noted in another study [<a href="#rid24">24</a>]. However, only some of the patients were tested for HLA-B27 in these studies.</p><p class="headingAnchor" id="H2458528110"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The exact pathophysiology or mechanism of the sterile bone inflammation is poorly understood, although CNO is probably an osteoclast-mediated disease. In addition, it is thought of as an autoinflammatory disease associated with alteration of the gut microbiome, and an imbalance between pro- and anti-inflammatory cytokines is suspected to play a role [<a href="#rid25">25</a>]. Available data so far point to the interplay among genetics, environmental, and immunologic factors as the causes of CNO. Infectious etiology does not seem to play a crucial role in the pathogenesis of CNO.</p><p>Serum cytokine studies have shed light on the possible disease pathogenesis of CNO. Monocytes/macrophages in CNO are skewed towards releasing proinflammatory cytokines such as interleukin (IL) 6, tumor necrosis factor (TNF) alpha, and<em> </em>IL-20, while there is sparse production of anti-inflammatory molecules such as IL-10 and IL-19 [<a href="#rid26">26,27</a>]. Dysregulation of IL-10 and IL-1-beta appears to lead to bone inflammation and bone loss in mouse models and in humans with autoinflammatory syndromes such as deficiency of IL-1 receptor antagonist (DIRA) [<a href="#rid28">28,29</a>]. A decrease in IL-10, for example, causes activation of NLR family pyrin domain-containing 3 (NLRP3) inflammasome, which in turn increases IL-1-beta and induces osteoclastogenesis via the receptor activator of nuclear factor kappa-B (RANK) receptor activator of nuclear factor kappa-B ligand (RANKL) pathway.</p><p>In one study, monocyte-derived cytokines, IL-1RA, IL-2R, IL-6, IL-12, eotaxin, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1-beta (MIP-1b), and RANTES were expressed significantly differently among children with CNO, Crohn disease, and healthy controls [<a href="#rid30">30</a>]. Similar cytokine profiles in children with juvenile idiopathic arthritis (JIA) and children with CNO suggest a partial common disease pathway. However, no autoantibodies or disease-specific T cell subsets have been identified in children with CNO.</p><p>An infectious etiology has been proposed, although antibiotic treatment, even prolonged courses, is ineffective in the majority of patients with CNO. Organisms found in some bone biopsy samples were subsequently felt to be contaminants [<a href="#rid31">31</a>]. However, some infectious burden/skewed microbiota have been implicated in triggering disease onset in Crohn disease [<a href="#rid32">32</a>], and a similar process may play a role in CNO. In a CRMO animal model, dietary changes were shown to alter the disease course [<a href="#rid33">33</a>]. A high-fat diet (HFD), which was accompanied with significant alterations in gut microbiome, protected the mice from bone inflammation [<a href="#rid33">33</a>]<em>.</em> Fecal transplant from HFD-fed mice protected the young mice fed with a regular diet from developing bone inflammation. However, there are no data available regarding diet and the microbiome in human CNO.</p><p class="headingAnchor" id="H3039534584"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The cardinal feature of CNO is bone pain of insidious onset. Affected children may have swelling over the painful area. There is usually focal tenderness with occasional warmth. CNO can be recurrent (episodic) or persistent (chronic). It can involve only one area (unifocal) or multiple bones (multifocal). The average number of lesions is three or four (range: two to six) [<a href="#rid10">10,24,34</a>].</p><p>CNO may affect any bone, but the metaphysis of the long bones of the lower extremities is the most common site, followed by the pelvis, vertebra, clavicle, long bones of the upper extremity, and mandible. Involvement of the skull is rare in CNO; therefore, an alternative diagnosis such as Langerhans cell histiocytosis (LCH) of bone should be sought in these patients (see <a class="local">'Differential diagnosis'</a> below). Isolated mandible disease (eg, Garré osteomyelitis, diffuse sclerosing osteomyelitis) is most likely in the spectrum of CNO [<a href="#rid35">35</a>].</p><p>In reports with long-term follow-up, most patients with unifocal presentation were found to have more lesions during further work-up (silent lesions) or have developed new lesions during the follow-up period. In one study, 54 percent of patients had unifocal disease at diagnosis, which dropped to 24 percent after further work-up and over time, and 29 percent of lesions were asymptomatic [<a href="#rid7">7</a>]. In a French study, there was progression from unifocal to multifocal disease over time. Only 7 percent remained unifocal after four years of follow-up [<a href="#rid10">10</a>]<em>. </em>Clavicle involvement was more common in the persistent unifocal group, and there were more males in the multifocal group.</p><p class="headingAnchor" id="H3410710796"><span class="h1">ASSOCIATED CONDITIONS</span><span class="headingEndMark"> — </span>CNO is associated with other conditions that primarily affect the skin, gut, or joints, such as psoriasis, palmoplantar pustulosis (PPP), acne, inflammatory bowel disease (IBD), spondyloarthropathy/enthesitis related arthritis (ERA), and, less commonly, pyoderma gangrenosum, Sweet syndrome, Takayasu arteritis, or granulomatosis with polyangiitis (GPA) [<a href="#rid6">6,36,37</a>]. PPP is the most common associated skin condition and usually worsens with CNO flares. PPP and psoriasis are included in one of the diagnostic criteria  (<a class="graphic graphic_table graphicRef121104" href="/z/d/graphic/121104.html" rel="external">table 1</a>). Some patients have one or more of these extraosseous conditions at the time of diagnosis, whereas others develop them later in the disease course [<a href="#rid11">11,12,38,39</a>]. Rarely, other organs can be involved, such as the kidneys (eg, proteinuria) [<a href="#rid40">40</a>]<em>.</em> Arthritis usually develops in the adjacent joints, though it can also happen in remote joints. Pelvic region lesions are more likely to be associated with sacroiliac arthritis than spinal lesions are.</p><p class="headingAnchor" id="H450372587"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>Children with persistent chronic bone pain and concerning imaging findings (see <a class="local">'Imaging'</a> below) should be referred to a pediatric rheumatologist for further evaluation.</p><p class="headingAnchor" id="H4277417992"><span class="h1">INITIAL TESTING</span><span class="headingEndMark"> — </span>The initial evaluation of suspected CNO/CRMO involves obtaining laboratory studies (complete blood count [CBC] with differential, C-reactive protein [CRP], and erythrocyte sedimentation rate [ESR]); imaging; and, in many patients, bone biopsy  (<a class="graphic graphic_table graphicRef121104" href="/z/d/graphic/121104.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H2462605700"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>A CBC, CRP, and ESR should be obtained in all children with suspected CNO to evaluate for infectious osteomyelitis (see <a class="local">'Differential diagnosis'</a> below). The majority of children with CNO have a normal CBC, CRP, and ESR [<a href="#rid10">10,11,39,41</a>], although some patients present with significantly elevated CRP and ESR [<a href="#rid7">7,39</a>]. There is no apparent correlation between the number or location of bone lesions and the laboratory findings.</p><p>Other screening labs are useful to exclude some differential diagnoses (see <a class="local">'Differential diagnosis'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uric acid and lactate dehydrogenase (LDH)</strong> – Elevated in children with tumor lysis syndrome from leukemia or other malignancies [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alkaline phosphatase (ALP), as a bone formation marker</strong> – Decreased in children with hypophosphatasia [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood cultures</strong> – Collect in children with suspected infectious osteomyelitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin C level</strong> – Obtain in a child with an unbalanced diet to rule out scurvy [<a href="#rid46">46</a>].</p><p></p><p>Urinary N terminal telopeptide (NTx) was reported in a small cohort study as a potential biomarker to monitor disease activity [<a href="#rid47">47</a>]. Serum cytokines, particularly interleukin (IL) 6 and C-C motif chemokine ligand 11 (CCL11), were reported as biomarkers distinguishing CNO from other diseases [<a href="#rid48">48</a>]. Further validation is needed for these biomarkers before clinical application.</p><p class="headingAnchor" id="H3346578573"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Initial imaging of patients with suspected CNO always starts with a radiograph of the painful site [<a href="#rid1">1,37,49</a>]. However, plain radiography has poor sensitivity for detection of CNO compared with magnetic resonance imaging (MRI), with only 15 percent of children having abnormal radiographic findings in one cohort [<a href="#rid50">50</a>]. Thus, MRI should be performed when radiographs are normal. In addition, clinically asymptomatic lesions, also known as "silent" lesions, are often detected by MRI. Vertebral "silent" lesions may lead to compression fracture [<a href="#rid51">51</a>]. Thus, whole-body MRI (WBMRI)  (<a class="graphic graphic_diagnosticimage graphicRef121698" href="/z/d/graphic/121698.html" rel="external">image 1</a>) remains the gold standard for diagnostic imaging and disease monitoring in CNO [<a href="#rid50">50,52-55</a>]. In MRI, fluid-sensitive sequences are most useful to accentuate the marrow changes in CNO. Either short tau inverse recovery (STIR) or fat saturation sequence is sufficient for initial screening. The optimal MRI protocol includes coronal STIR of the entire body, sagittal STIR of the entire spine, axial STIR of the pelvis and knee, and sagittal STIR of both ankles, all without contrast. However, contrast is necessary to determine the specific pattern if there is a high suspicion of infection or malignancy.</p><p>Other imaging modalities are not reasonable alternatives to MRI because of their poor sensitivity and risk of delaying diagnosis and corresponding treatment. Computed tomography (CT) has less value due to its lack of sensitivity in distinguishing active disease from chronic damage. Bone scintigraphy and positron emission tomography (PET)-CT are sometimes used to offer a whole-body level assessment in order to identify all lesions. However, both are radiation-based techniques, sensitivity of bone scintigraphy is lower than MRI [<a href="#rid56">56</a>], and it is more difficult to interpret bone scintigraphy results in children with growing bones due to the presence of physiologic uptake at the growth plates, where CNO lesions are commonly found.</p><p>Typical findings of CNO in each type of imaging are listed below:</p><p class="bulletIndent1"><span class="glyph">●</span>Radiographs (and CT)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lytic lesions  (<a class="graphic graphic_diagnosticimage graphicRef121691" href="/z/d/graphic/121691.html" rel="external">image 2</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sclerosis and cortical irregularity  (<a class="graphic graphic_diagnosticimage graphicRef121692" href="/z/d/graphic/121692.html" rel="external">image 3</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hyperostosis  (<a class="graphic graphic_diagnosticimage graphicRef121693" href="/z/d/graphic/121693.html" rel="external">image 4</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kyphosis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vertebral body height loss or plana  (<a class="graphic graphic_diagnosticimage graphicRef121694" href="/z/d/graphic/121694.html" rel="external">image 5</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Growth plate bony bar (also called a physeal bar; a bony or fibrous bridge between the epiphysis and metaphysis that forms due to interruption of the normal growth plate cartilage)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MRI, including WBMRI</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased intensity of STIR signal within bone marrow  (<a class="graphic graphic_diagnosticimage graphicRef121696" href="/z/d/graphic/121696.html" rel="external">image 6</a> and <a class="graphic graphic_diagnosticimage graphicRef121698" href="/z/d/graphic/121698.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef121699" href="/z/d/graphic/121699.html" rel="external">image 7</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased intensity of STIR signal within surrounding tissue  (<a class="graphic graphic_diagnosticimage graphicRef121696" href="/z/d/graphic/121696.html" rel="external">image 6</a> and <a class="graphic graphic_diagnosticimage graphicRef121698" href="/z/d/graphic/121698.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef121699" href="/z/d/graphic/121699.html" rel="external">image 7</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bony expansion  (<a class="graphic graphic_diagnosticimage graphicRef121700" href="/z/d/graphic/121700.html" rel="external">image 8</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone scintigraphy</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased uptake  (<a class="graphic graphic_diagnosticimage graphicRef121695" href="/z/d/graphic/121695.html" rel="external">image 9</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PET-CT</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased uptake within a localized region</p><p></p><p class="headingAnchor" id="H3351969672"><span class="h2">Biopsy of bone and other sites</span><span class="headingEndMark"> — </span>Microbiologic and pathologic studies from bone biopsy are important because infectious osteomyelitis and malignancy are the two major categories of diseases with similar presentation (see <a class="local">'Differential diagnosis'</a> below). However, children with a classic presentation that includes a well appearance, normal laboratory findings, symmetrical lesions in typical sites such as the metaphysis of long bones, or associated conditions (psoriasis, palmoplantar pustulosis [PPP], inflammatory bowel disease [IBD], spondyloarthropathy/enthesitis related arthritis [ERA]) may be spared from a bone biopsy prior to treatment  (<a class="graphic graphic_table graphicRef121104" href="/z/d/graphic/121104.html" rel="external">table 1</a>) [<a href="#rid7">7,37,41</a>]. In children with a unifocal lesion involving a bone other than the clavicle, even if it is in a typical location, a bone biopsy is recommended. A diaphyseal lesion is rare in CNO and more commonly seen in osteosarcoma, so a biopsy is necessary to exclude primary bone malignancies [<a href="#rid57">57</a>]. Bone marrow and/or lymph node biopsy are indicated when clinical findings suggest leukemia or lymphoma.</p><p>In most series, biopsy rates reach 70 to 80 percent, in some patients more than once. The Jansson scoring system  (<a class="graphic graphic_table graphicRef121104" href="/z/d/graphic/121104.html" rel="external">table 1</a>) was tested retrospectively in one study, and it was found that 27 percent of biopsies could have been prevented or delayed [<a href="#rid10">10</a>]. In another study, 12 patients were referred to a rheumatology clinic before the biopsy, and nine of them did not need biopsy because multiple lesions were present (found after bone scan or MRI), there were siblings with CRMO, or the lesion was in the clavicle [<a href="#rid7">7</a>].</p><p>Sites of bone biopsy are often determined by surgeons and interventional radiologists based on the feasibility of accessing the lesion [<a href="#rid37">37</a>]. Biopsy of multiple sites may be performed to enhance the sensitivity of bone biopsy when indicated. Repeated biopsies may be required in patients with an unusual presentation or atypical clinical course. Special staining such as CD1a and S100 are commonly performed to rule out Langerhans cell histiocytosis (LCH).</p><p>Although there is no distinct diagnostic feature in bone pathology for CNO, common findings include:</p><p class="bulletIndent1"><span class="glyph">●</span>Destruction of normal bone structure and presence of neutrophils, monocytes, lymphocytes, and plasma cells during early phases [<a href="#rid1">1</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A predominance of fibrosis and sparse immune cells during later phases [<a href="#rid1">1</a>]</p><p></p><p>A mixture of fibrosis and inflammation, as well as normal bone, is also often reported [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H3867773200"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>CNO/CRMO should be suspected in any child with insidious-onset bone pain based upon clinical criteria. The Jansson [<a href="#rid41">41</a>] and Bristol [<a href="#rid7">7</a>] criteria, which include typical features of CNO  (<a class="graphic graphic_table graphicRef121104" href="/z/d/graphic/121104.html" rel="external">table 1</a>), are most commonly used.</p><p>Biopsy of the lesion is generally needed to make the diagnosis (see <a class="local">'Initial testing'</a> above). The diagnosis remains a "diagnosis of exclusion" because of the nonspecific features in every aspect of CNO (clinical, laboratory, imaging, and pathology). The lack of specific features also usually results in a delay in the diagnosis of CNO, with a median time to diagnosis of approximately 15 months in many series [<a href="#rid7">7,58</a>]. Patients, particularly those with solitary lesions, may be misdiagnosed as having bacterial osteomyelitis and treated with long-term antibiotics or undergo unnecessary procedures even after culture-negative bone biopsies since pathologic findings of CNO are indistinguishable from infectious osteomyelitis [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H3555325326"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The most common alternative diagnoses include infectious osteomyelitis and malignancy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukemia</strong> – Leukemia (most commonly acute lymphoblastic leukemia/lymphoblastic lymphoma [ALL/ABL], but acute myeloid leukemia [AML] also possible) may present as bone pain with abnormal short tau inverse recovery (STIR) signal within bone marrow on magnetic resonance imaging (MRI). Plain radiographs often show metaphyseal bands and a periosteal reaction. Bone pain is mostly due to aseptic osteonecrosis, typically waking the child from sleep. The peak age of onset is two to five years, and it mostly affects males. Greater than 60 percent children with leukemia have hepatosplenomegaly, and 50 percent have lymphadenopathy. Fever, weight loss, and pallor are common. Complete blood count (CBC) with differential may show blasts and/or cytopenia. Thrombocytopenia is present in 75 percent of cases. Bone marrow biopsy confirms the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6244.html" rel="external">"Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hodgkin lymphoma (HL)</strong> – HL commonly affects children aged between 15 and 19 years. Systemic complaints such as fatigue and weight loss are common in addition to chronic bone pain with similar imaging findings as in CNO. Lymphadenopathy and mediastinal mass may prompt lymph node biopsy for final confirmation of lymphoma. Cases of lymphoma misdiagnosed as CNO have been reported [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/6246.html" rel="external">"Overview of Hodgkin lymphoma in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Langerhans cell histiocytosis (LCH) of bone</strong> – LCH (eosinophilic granuloma) of bone most commonly occurs in children between 5 to 10 years of age. Most patients complain of pain in a localized area of bone, and examination usually reveals a raised, soft, tender spot. Radiographs may show osteolytic lesions as a "punch-out" pattern. Usually, only one bone is involved, most commonly the skull, and there is a single lesion. CD1a staining on bone biopsy or other affected tissue biopsy reveals the presence of histiocytosis. (See  <a class="medical medical_review" href="/z/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Lytic bone lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-LCH histiocytosis</strong> – Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) may mimic CNO. ECD is rare in children and is associated with arginine vasopressin deficiency (previously called central diabetes insipidus). Bone involvement in ECD most commonly manifests as mild but persistent juxta-articular pain, particularly in the lower extremities. Bilateral and symmetric osteosclerosis of the diaphysis of the long bones is nearly universal. RDD is a macrophage-related disease that often affects lymph nodes but can also result in lytic bone lesions. Histology from bone biopsy, lymph nodes, or other affected areas is most useful in making the diagnosis. Genetic testing from bone biopsy can confirm ECD. (See  <a class="medical medical_review" href="/z/d/html/13942.html" rel="external">"Erdheim-Chester disease"</a> and  <a class="medical medical_review" href="/z/d/html/2871.html" rel="external">"Peripheral lymphadenopathy in children: Etiology", section on 'Rosai-Dorfman disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary malignant bone disease</strong> – Primary bone malignancies include osteosarcoma, chondrosarcoma, Ewing sarcoma, and primary non-Hodgkin lymphoma of bone (PLB). Clinical symptoms of these diseases may mimic CNO, but MRI findings usually show distinct patterns with extensive bone destruction in all except PLB. Radiographs may show disorganized periosteal reaction, new bone formation, cortical bone destruction, or soft tissue mass. Osteosarcoma and Ewing sarcoma commonly affect diaphysis or metadiaphysis of the long bones. (See  <a class="medical medical_review" href="/z/d/html/7722.html" rel="external">"Osteosarcoma: Epidemiology, pathology, clinical presentation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7724.html" rel="external">"Chondrosarcoma"</a> and  <a class="medical medical_review" href="/z/d/html/7744.html" rel="external">"Clinical presentation, staging, and prognostic factors of Ewing sarcoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign bone tumor</strong> – Benign tumors of the bone include osteoid osteoma, enchondroma, osteoblastoma and chondroblastoma, and cystic bone tumors. The majority have distinct features on radiographs and can be diagnosed with such. (See  <a class="medical medical_review" href="/z/d/html/6294.html" rel="external">"Nonmalignant bone lesions in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic infectious osteomyelitis</strong> – Hematogenous osteomyelitis may present with focal bone pain and limitation of function. Constitutional symptoms and elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are common. Fever may or may not be present. Blood and bone cultures are positive in &gt;80 percent of the cases. Radiographs may show lytic lesions or periosteal reactions. MRI findings may show subperiosteal or soft tissue collections of pus. (See  <a class="medical medical_review" href="/z/d/html/6067.html" rel="external">"Hematogenous osteomyelitis in children: Evaluation and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avascular necrosis (AVN)</strong> – Osteonecrosis may affect the long bones at the metaphysis and/or epiphysis and present with focal pain worsening after weight bearing. MRI shows a single-density line separating normal and ischemic bone on T1-weighted images. Risk factors such as chronic glucocorticoid use often exist in these patients. (See  <a class="medical medical_review" href="/z/d/html/5613.html" rel="external">"Treatment of nontraumatic hip osteonecrosis (avascular necrosis of the femoral head) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin C deficiency </strong>– Vitamin C deficiency is commonly seen in picky eaters and children with malnutrition. Common manifestations are gingivitis, bruising, and musculoskeletal pain. Characteristic findings on MRI are sclerotic and lucent metaphyseal bands, with periosteal reaction and adjacent soft-tissue edema. Vitamin C level is low in these children. (See  <a class="medical medical_review" href="/z/d/html/5367.html" rel="external">"Overview of water-soluble vitamins", section on 'Vitamin C (ascorbic acid)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic arthritis </strong>– Psoriatic arthritis, inflammatory bowel disease (IBD) associated arthritis, and enthesitis related arthritis (ERA) may present with bone pain adjacent to the affected joints. Inflammatory bony changes may be seen in the sacrum or ilium adjacent to the joint when the sacroiliac joint is affected in ERA. Children with psoriatic arthritis and psoriasis may develop coexisting CNO. Dactylitis and signs of chronic arthritis are key features. (See  <a class="medical medical_review" href="/z/d/html/16630.html" rel="external">"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/6421.html" rel="external">"Spondyloarthritis in children"</a> and  <a class="medical medical_review" href="/z/d/html/7787.html" rel="external">"Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amplified pain syndromes (AMPS) including complex regional pain syndrome (CRPS)</strong> – AMPS are often associated with chronic diseases and may coexist with CNO. Typically, there is allodynia (pain to touch) of the involved body part(s), with or without focal swelling, discoloration, or temperature changes. MRI can show bony edema and small joint effusions, which helps distinguish AMPS/CRPS from CNO in the appropriate clinical setting. (See  <a class="medical medical_review" href="/z/d/html/6411.html" rel="external">"Complex regional pain syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypophosphatasia</strong> – Hypophosphatasia is a hereditary metabolic bone disease caused by pathogenic variants of the tissue-nonspecific alkaline phosphatase (<em>TNSALP</em>) gene on chromosome 1p36.1. Reduced enzyme activity causes IBD that mimics CNO. MRI findings are identical [<a href="#rid44">44,45,61</a>]. Low alkaline phosphatase, elevated phosphorus, elevated pyridoxal-50-phosphate and phosphoethanolamine, and genetic testing are diagnostic.</p><p></p><p class="headingAnchor" id="H2600285224"><span class="h1">MANAGEMENT</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy – </strong>The initial therapy for most children with CNO is daily nonsteroidal antiinflammatory drugs (NSAIDs) at standard doses [<a href="#rid1">1,12,37,55,62,63</a>]. Up to 50 percent of patients achieve clinical remission within the first year of starting an NSAID, but relapse is common, and new lesions may develop. For those who respond, there is no clear guideline on total duration of NSAID treatment. Most clinicians trial patients off NSAIDs if there are no clinical symptoms and magnetic resonance imaging (MRI) shows no or minimum disease activity after one to two years of treatment. Close follow-up is critical in order to capture children with recurrence of the disease. Children with episodic flares may only require retreatment with NSAIDs for a few months. However, children with frequent flares may require longer treatment with NSAIDs or additional medications.</p><p></p><p class="bulletIndent1">In a prospective, observational study of 37 children and adolescents with CNO, 43 percent (16 of 37) had achieved clinical remission after six months of <a class="drug drug_pediatric" data-topicid="12630" href="/z/d/drug information/12630.html" rel="external">naproxen</a> treatment [<a href="#rid63">63</a>]. After 12 months of therapy, 62 percent were in clinical remission, no patient reported morning stiffness or functional impairment of the legs, only five patients (14 percent) noted local swelling, and disease activity and severity scores had decreased. However, only 14 percent had complete resolution of MRI findings by 6 months and 27 percent by 12 months. In addition, 41 percent had radiologic relapses, although 67 percent were asymptomatic. In contrast, a retrospective series of 56 patients reported clinical remission in all patients after three months of NSAID therapy, although 50 percent relapsed after a median of 2.4 years [<a href="#rid12">12</a>]. In a small cohort study (n = 9) that used MRI scoring as the main outcome measurement, children with CNO showed no improvement in either the total number of lesions or the maximum bone edema score from MRI after a median of 7.3 months on NSAIDs, but soft tissue inflammation and periosteal reaction significantly decreased [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapy for patients with spinal lesions –</strong> In children with active spinal lesions, <a class="drug drug_pediatric" data-topicid="13381" href="/z/d/drug information/13381.html" rel="external">infliximab</a> with or without bisphosphonate [<a href="#rid62">62</a>] and bisphosphonate alone [<a href="#rid64">64,65</a>] in addition to NSAIDs at the start of therapy showed favorable outcomes in small cohorts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease –</strong> In children with CNO who have persistently active symptoms and abnormal MRI findings despite a four-to-six-week trial of NSAID therapy, additional treatments including disease-modifying antirheumatic drugs (DMARDs), tumor necrosis factor (TNF) inhibitors, and/or bisphosphonates are necessary to induce remission and reduce skeletal damage [<a href="#rid1">1,66</a>]. There are no head-to-head comparisons of efficacy of these treatments. However, retrospective studies suggest that TNF inhibitors and bisphosphonates have better response rates than DMARDs and glucocorticoids [<a href="#rid10">10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring –</strong> Disease activity monitoring includes regular imaging (preferably MRI) of discrete lesions, particularly symptomatic ones, and physical assessment by a pediatric rheumatologist in order to determine treatment options and duration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care –</strong> Management of CNO also includes supportive care such as appropriate physical and occupation therapy, as well as periodic laboratory screening for medication toxicity.</p><p></p><p class="headingAnchor" id="H993832001"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The disease course can be variable, from mild, intermittent episodes to an unrelenting course with uncontrolled inflammation causing significant morbidity including bone deformities, fractures, growth failure, arthritis, neurologic symptoms (particularly from spinal involvement), refractory and persistent pain syndromes, and psychosocial dysfunction resulting in poor quality of life (QOL) [<a href="#rid10">10,52,62,64,67</a>]. Leg-length discrepancy and angulation secondary to growth plate damage also may occur. Early diagnosis and treatment may prevent or decrease complications of the disease.</p><p>In a small, longitudinal, follow-up study, the outcomes of 17 children with CNO varied from complete remission to persistent, active inflammation revealed by magnetic resonance imaging (MRI) even after a median of 15 years [<a href="#rid52">52</a>]. In the largest cohort (n = 178), after a median of four years, only 43 percent of patients achieved remission, while 40 percent (27 of 67) remained on therapy [<a href="#rid10">10</a>]. Among those with active disease, 72 percent (70 of 97) were continuing treatment. These results underscore the importance of close monitoring by a pediatric rheumatologist during childhood and continuing follow-up with a rheumatologist into adulthood.</p><p>Factors associated with poorer prognosis (disease that is more difficult to control, with lower remission rates and higher usage of tumor necrosis factor [TNF] inhibitors and/or bisphosphonate, and increased risk of arthritis) include [<a href="#rid6">6,12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Multifocal bone pain, particularly involvement of lower-extremity bones or spine; also vertebral fractures</p><p class="bulletIndent1"><span class="glyph">●</span>Longstanding, untreated inflammation and higher inflammatory markers</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>Extraosseous manifestations including arthritis, as well as acne, inflammatory bowel disease (IBD), and palmoplantar pustulosis (PPP)</p><p></p><p class="headingAnchor" id="H2714763881"><span class="h1">RESOURCES</span><span class="headingEndMark"> — </span>Clinicians and family representatives have aimed to increase the awareness of CNO in the general and medical communities through <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fcrmoawareness.org%2F&amp;token=g8rc3DCsaXqjvGHGOL0Q3y4BEC%2B8JXnlPCxwqXYAmY8Jc2KfM%2BFD1elvea%2FYJc6Y&amp;TOPIC_ID=118084" target="_blank">online resources</a> and <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fcrmoawareness.org%2Fwp-content%2Fuploads%2F2018%2F01%2FCNO_CRMO_CaregiverLong_Final.pdf&amp;token=g8rc3DCsaXqjvGHGOL0Q30TYbDaPpkxqFDYdrlH6PmmuSjuRfVAhxVafVY3RBqmUUKl4nQlAn6Qvo8GbQnxjjnzDIbZyypiJG90RG84Pk6yKUqgvMhNBemqXEuciuuFR&amp;TOPIC_ID=118084" target="_blank">caregiver handouts</a>.</p><p class="headingAnchor" id="H2317214132"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology – </strong>Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO) is a chronic inflammatory bone disorder affecting primarily children. Both terms are used, although CRMO is often perceived as the more severe form, and CNO is used as the general term for the condition. (See <a class="local">'Introduction'</a> above and <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis – </strong>CNO has been reported worldwide with female predominance. It is a rare disease, but lack of awareness of the condition has contributed to underdiagnosis and reporting. The exact pathogenesis is unknown. Both genetic and environmental factors are thought to contribute to the underlying inflammation. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Genetics and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestation – </strong>The cardinal feature of CNO is bone pain of insidious onset. CNO is also associated with other conditions such as psoriasis, palmoplantar pustulosis (PPP), inflammatory bowel disease (IBD), and spondyloarthropathy. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Associated conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial testing – </strong>The diagnosis of suspected CNO/CRMO involves obtaining laboratory studies (complete blood count [CBC], C-reactive protein [CRP], and/or erythrocyte sedimentation rate [ESR]); imaging; and, in many patients, bone biopsy. Whole-body magnetic resonance imaging (WBMRI) is the gold-standard imaging modality for diagnostic and staging purposes. (See <a class="local">'Initial testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis – </strong>CNO/CRMO should be suspected in any child with insidious-onset bone pain. Two commonly used diagnostic criteria, Jansson and Bristol, that include typical features of CNO are shown in the table  (<a class="graphic graphic_table graphicRef121104" href="/z/d/graphic/121104.html" rel="external">table 1</a>). Biopsy of the lesion is generally needed to make the diagnosis. The lack of features specific to CNO usually results in a delay in the diagnosis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis – </strong>The differential diagnosis includes infectious osteomyelitis, Langerhans cell histiocytosis (LCH), and malignancies that involve the bone (eg, leukemia, lymphoma, osteosarcoma). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management – </strong>Nonsteroidal antiinflammatory drugs (NSAIDs) are the first line of treatment for most patients. Additional treatment options for patients with active spinal lesions or in those who have persistently active symptoms and abnormal magnetic resonance imaging (MRI) findings despite NSAID therapy include tumor necrosis factor (TNF) inhibitors, bisphosphonates, and disease-modifying antirheumatic drugs (DMARDs). Patients are monitored with focal MRI studies and by physical assessment. (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis – </strong>The disease course can be variable, from mild, intermittent episodes to an unrelenting course with uncontrolled inflammation causing significant morbidity. Early diagnosis and treatment may prevent or decrease complications of the disease. (See <a class="local">'Prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hedrich CM, Hofmann SR, Pablik J, et al. Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO). Pediatr Rheumatol Online J 2013; 11:47.</a></li><li><a class="nounderline abstract_t">Giedion A, Holthusen W, Masel LF, Vischer D. [Subacute and chronic "symmetrical" osteomyelitis]. Ann Radiol (Paris) 1972; 15:329.</a></li><li><a class="nounderline abstract_t">Probst FP, Björksten B, Gustavson KH. Radiological aspect of chronic recurrent multifocal osteomyelitis. Ann Radiol (Paris) 1978; 21:115.</a></li><li><a class="nounderline abstract_t">Bj0rkstén B, Boquist L. Histopathological aspects of chronic recurrent multifocal osteomyelitis. J Bone Joint Surg Br 1980; 62:376.</a></li><li><a class="nounderline abstract_t">Greenwood S, Leone A, Cassar-Pullicino VN. SAPHO and Recurrent Multifocal Osteomyelitis. Radiol Clin North Am 2017; 55:1035.</a></li><li><a class="nounderline abstract_t">Roderick MR, Sen ES, Ramanan AV. Chronic recurrent multifocal osteomyelitis in children and adults: current understanding and areas for development. Rheumatology (Oxford) 2018; 57:41.</a></li><li><a class="nounderline abstract_t">Roderick MR, Shah R, Rogers V, et al. Chronic recurrent multifocal osteomyelitis (CRMO) - advancing the diagnosis. Pediatr Rheumatol Online J 2016; 14:47.</a></li><li><a class="nounderline abstract_t">Hofmann SR, Kapplusch F, Girschick HJ, et al. Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Curr Osteoporos Rep 2017; 15:542.</a></li><li><a class="nounderline abstract_t">Jansson AF, Grote V, ESPED Study Group. Nonbacterial osteitis in children: data of a German Incidence Surveillance Study. Acta Paediatr 2011; 100:1150.</a></li><li><a class="nounderline abstract_t">Wipff J, Costantino F, Lemelle I, et al. A large national cohort of French patients with chronic recurrent multifocal osteitis. Arthritis Rheumatol 2015; 67:1128.</a></li><li><a class="nounderline abstract_t">Borzutzky A, Stern S, Reiff A, et al. Pediatric chronic nonbacterial osteomyelitis. Pediatrics 2012; 130:e1190.</a></li><li><a class="nounderline abstract_t">Schnabel A, Range U, Hahn G, et al. Treatment Response and Longterm Outcomes in Children with Chronic Nonbacterial Osteomyelitis. J Rheumatol 2017; 44:1058.</a></li><li><a class="nounderline abstract_t">Kaiser D, Bolt I, Hofer M, et al. Chronic nonbacterial osteomyelitis in children: a retrospective multicenter study. Pediatr Rheumatol Online J 2015; 13:25.</a></li><li><a class="nounderline abstract_t">Silier CCG, Greschik J, Gesell S, et al. Chronic non-bacterial osteitis from the patient perspective: a health services research through data collected from patient conferences. BMJ Open 2017; 7:e017599.</a></li><li><a class="nounderline abstract_t">Cox AJ, Darbro BW, Laxer RM, et al. Correction: Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO). PLoS One 2017; 12:e0181222.</a></li><li><a class="nounderline abstract_t">Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: A multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38:417.</a></li><li><a class="nounderline abstract_t">Grosse J, Chitu V, Marquardt A, et al. Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease. Blood 2006; 107:3350.</a></li><li><a class="nounderline abstract_t">Safra N, Johnson EG, Lit L, et al. Clinical manifestations, response to treatment, and clinical outcome for Weimaraners with hypertrophic osteodystrophy: 53 cases (2009-2011). J Am Vet Med Assoc 2013; 242:1260.</a></li><li><a class="nounderline abstract_t">Stern SM, Ferguson PJ. Autoinflammatory bone diseases. Rheum Dis Clin North Am 2013; 39:735.</a></li><li><a class="nounderline abstract_t">Beck C, Girschick HJ, Morbach H, et al. Mutation screening of the IL-1 receptor antagonist gene in chronic non-bacterial osteomyelitis of childhood and adolescence. Clin Exp Rheumatol 2011; 29:1040.</a></li><li><a class="nounderline abstract_t">Golla A, Jansson A, Ramser J, et al. Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3-18q22. Eur J Hum Genet 2002; 10:217.</a></li><li><a class="nounderline abstract_t">Ha YJ, Park YB, Son MK, et al. Predictive factors related to progression toward rheumatoid arthritis in Korean patients with undifferentiated arthritis. Rheumatol Int 2012; 32:1555.</a></li><li><a class="nounderline abstract_t">Bousvaros A, Marcon M, Treem W, et al. Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children. Dig Dis Sci 1999; 44:2500.</a></li><li><a class="nounderline abstract_t">Walsh P, Manners PJ, Vercoe J, et al. Chronic recurrent multifocal osteomyelitis in children: nine years' experience at a statewide tertiary paediatric rheumatology referral centre. Rheumatology (Oxford) 2015; 54:1688.</a></li><li><a class="nounderline abstract_t">Cox AJ, Zhao Y, Ferguson PJ. Chronic Recurrent Multifocal Osteomyelitis and Related Diseases-Update on Pathogenesis. Curr Rheumatol Rep 2017; 19:18.</a></li><li><a class="nounderline abstract_t">Scianaro R, Insalaco A, Bracci Laudiero L, et al. Deregulation of the IL-1β axis in chronic recurrent multifocal osteomyelitis. Pediatr Rheumatol Online J 2014; 12:30.</a></li><li><a class="nounderline abstract_t">Hofmann SR, Kapplusch F, Mäbert K, Hedrich CM. The molecular pathophysiology of chronic non-bacterial osteomyelitis (CNO)-a systematic review. Mol Cell Pediatr 2017; 4:7.</a></li><li><a class="nounderline abstract_t">Ferguson PJ, Laxer RM. New discoveries in CRMO: IL-1β, the neutrophil, and the microbiome implicated in disease pathogenesis in Pstpip2-deficient mice. Semin Immunopathol 2015; 37:407.</a></li><li><a class="nounderline abstract_t">Greenhill CJ, Jones GW, Nowell MA, et al. Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Res Ther 2014; 16:419.</a></li><li><a class="nounderline abstract_t">Hofmann SR, Kubasch AS, Range U, et al. Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO). Rheumatol Int 2016; 36:769.</a></li><li><a class="nounderline abstract_t">Girschick HJ, Raab P, Surbaum S, et al. Chronic non-bacterial osteomyelitis in children. Ann Rheum Dis 2005; 64:279.</a></li><li><a class="nounderline abstract_t">Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013; 62:1505.</a></li><li><a class="nounderline abstract_t">Lukens JR, Gurung P, Vogel P, et al. Dietary modulation of the microbiome affects autoinflammatory disease. Nature 2014; 516:246.</a></li><li><a class="nounderline abstract_t">Schnabel A, Range U, Hahn G, et al. Unexpectedly high incidences of chronic non-bacterial as compared to bacterial osteomyelitis in children. Rheumatol Int 2016; 36:1737.</a></li><li><a class="nounderline abstract_t">Padwa BL, Dentino K, Robson CD, et al. Pediatric Chronic Nonbacterial Osteomyelitis of the Jaw: Clinical, Radiographic, and Histopathologic Features. J Oral Maxillofac Surg 2016; 74:2393.</a></li><li><a class="nounderline abstract_t">Costa-Reis P, Sullivan KE. Chronic recurrent multifocal osteomyelitis. J Clin Immunol 2013; 33:1043.</a></li><li><a class="nounderline abstract_t">Zhao Y, Dedeoglu F, Ferguson PJ, et al. Physicians' Perspectives on the Diagnosis and Treatment of Chronic Nonbacterial Osteomyelitis. Int J Rheumatol 2017; 2017:7694942.</a></li><li><a class="nounderline abstract_t">Vittecoq O, Said LA, Michot C, et al. Evolution of chronic recurrent multifocal osteitis toward spondylarthropathy over the long term. Arthritis Rheum 2000; 43:109.</a></li><li><a class="nounderline abstract_t">Jansson A, Renner ED, Ramser J, et al. Classification of non-bacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology (Oxford) 2007; 46:154.</a></li><li><a class="nounderline abstract_t">Pastore S, Ferrara G, Monasta L, et al. Chronic nonbacterial osteomyelitis may be associated with renal disease and bisphosphonates are a good option for the majority of patients. Acta Paediatr 2016; 105:e328.</a></li><li><a class="nounderline abstract_t">Jansson AF, Müller TH, Gliera L, et al. Clinical score for nonbacterial osteitis in children and adults. Arthritis Rheum 2009; 60:1152.</a></li><li><a class="nounderline abstract_t">Sevinir B, Demirkaya M, Baytan B, Güneş AM. Hyperuricemia and tumor lysis syndrome in children with non-Hodgkin's lymphoma and acute lymphoblastic leukemia. Turk J Haematol 2011; 28:52.</a></li><li><a class="nounderline abstract_t">Alavi S, Arzanian MT, Abbasian MR, Ashena Z. Tumor lysis syndrome in children with non-Hodgkin lymphoma. Pediatr Hematol Oncol 2006; 23:65.</a></li><li><a class="nounderline abstract_t">Whyte MP, Wenkert D, McAlister WH, et al. Chronic recurrent multifocal osteomyelitis mimicked in childhood hypophosphatasia. J Bone Miner Res 2009; 24:1493.</a></li><li><a class="nounderline abstract_t">Girschick HJ, Mornet E, Beer M, et al. Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy. BMC Pediatr 2007; 7:3.</a></li><li><a class="nounderline abstract_t">Kinlin LM, Blanchard AC, Silver S, Morris SK. Scurvy as a mimicker of osteomyelitis in a child with autism spectrum disorder. Int J Infect Dis 2018; 69:99.</a></li><li><a class="nounderline abstract_t">Miettunen PM, Wei X, Kaura D, et al. Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO). Pediatr Rheumatol Online J 2009; 7:2.</a></li><li><a class="nounderline abstract_t">Hofmann SR, Böttger F, Range U, et al. Serum Interleukin-6 and CCL11/Eotaxin May Be Suitable Biomarkers for the Diagnosis of Chronic Nonbacterial Osteomyelitis. Front Pediatr 2017; 5:256.</a></li><li><a class="nounderline abstract_t">Iyer RS, Thapa MM, Chew FS. Chronic recurrent multifocal osteomyelitis: review. AJR Am J Roentgenol 2011; 196:S87.</a></li><li><a class="nounderline abstract_t">Fritz J, Tzaribatchev N, Claussen CD, et al. Chronic recurrent multifocal osteomyelitis: comparison of whole-body MR imaging with radiography and correlation with clinical and laboratory data. Radiology 2009; 252:842.</a></li><li><a class="nounderline abstract_t">Hofmann SR, Schnabel A, Rösen-Wolff A, et al. Chronic Nonbacterial Osteomyelitis: Pathophysiological Concepts and Current Treatment Strategies. J Rheumatol 2016; 43:1956.</a></li><li><a class="nounderline abstract_t">Voit AM, Arnoldi AP, Douis H, et al. Whole-body Magnetic Resonance Imaging in Chronic Recurrent Multifocal Osteomyelitis: Clinical Longterm Assessment May Underestimate Activity. J Rheumatol 2015; 42:1455.</a></li><li><a class="nounderline abstract_t">Roderick M, Shah R, Finn A, Ramanan AV. Efficacy of pamidronate therapy in children with chronic non-bacterial osteitis: disease activity assessment by whole body magnetic resonance imaging. Rheumatology (Oxford) 2014; 53:1973.</a></li><li><a class="nounderline abstract_t">Guérin-Pfyffer S, Guillaume-Czitrom S, Tammam S, Koné-Paut I. Evaluation of chronic recurrent multifocal osteitis in children by whole-body magnetic resonance imaging. Joint Bone Spine 2012; 79:616.</a></li><li><a class="nounderline abstract_t">Zhao Y, Laxer R, Ferguson P. Treatment Advances in Chronic Non-Bacterial Osteomyelitis and Other Autoinflammatory Bone Conditions. Curr Treatm Opt Rheumatol 2017; 3:17.</a></li><li><a class="nounderline abstract_t">Morbach H, Schneider P, Schwarz T, et al. Comparison of magnetic resonance imaging and 99mTechnetium-labelled methylene diphosphonate bone scintigraphy in the initial assessment of chronic non-bacterial osteomyelitis of childhood and adolescents. Clin Exp Rheumatol 2012; 30:578.</a></li><li><a class="nounderline abstract_t">von Kalle T, Heim N, Hospach T, et al. Typical patterns of bone involvement in whole-body MRI of patients with chronic recurrent multifocal osteomyelitis (CRMO). Rofo 2013; 185:655.</a></li><li class="breakAll">Oliver M, Lee T, Halpern-Felsher B, et al. Disease Burden and Social Impact of Chronic Nonbacterial Osteomyelitis on Affected Children and Young Adults [abstract]. Arthritis Rheumatol 2017; 69(Suppl. 4).</li><li><a class="nounderline abstract_t">Oberc A, Sułko J. Chronic recurrent multifocal osteomyelitis (CRMO) in children - single-centre clinical observations and experience. Ortop Traumatol Rehabil 2014; 16:297.</a></li><li><a class="nounderline abstract_t">Haque SA, Shad A, Ozdemirli M, et al. A thirteen year old female with primary T-cell rich B-cell lymphoma of bone masquerading as chronic recurrent multifocal osteomyelitis. Pediatr Rep 2009; 1:e3.</a></li><li><a class="nounderline abstract_t">Beck C, Morbach H, Wirth C, et al. Whole-body MRI in the childhood form of hypophosphatasia. Rheumatol Int 2011; 31:1315.</a></li><li><a class="nounderline abstract_t">Zhao Y, Chauvin NA, Jaramillo D, Burnham JM. Aggressive Therapy Reduces Disease Activity without Skeletal Damage Progression in Chronic Nonbacterial Osteomyelitis. J Rheumatol 2015; 42:1245.</a></li><li><a class="nounderline abstract_t">Beck C, Morbach H, Beer M, et al. Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment. Arthritis Res Ther 2010; 12:R74.</a></li><li><a class="nounderline abstract_t">Hospach T, Langendoerfer M, von Kalle T, et al. Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate. Eur J Pediatr 2010; 169:1105.</a></li><li><a class="nounderline abstract_t">Kerrison C, Davidson JE, Cleary AG, Beresford MW. Pamidronate in the treatment of childhood SAPHO syndrome. Rheumatology (Oxford) 2004; 43:1246.</a></li><li><a class="nounderline abstract_t">Zhao Y, Wu EY, Oliver MS, et al. Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. Arthritis Care Res (Hoboken) 2018; 70:1228.</a></li><li><a class="nounderline abstract_t">Gleeson H, Wiltshire E, Briody J, et al. Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape. J Rheumatol 2008; 35:707.</a></li></ol></div><div id="topicVersionRevision">Topic 118084 Version 6.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359092" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4403064" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : [Subacute and chronic "symmetrical" osteomyelitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/677736" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Radiological aspect of chronic recurrent multifocal osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7410472" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Histopathological aspects of chronic recurrent multifocal osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28774447" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : SAPHO and Recurrent Multifocal Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486628" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chronic recurrent multifocal osteomyelitis in children and adults: current understanding and areas for development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27576444" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Chronic recurrent multifocal osteomyelitis (CRMO) - advancing the diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29080202" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21352353" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Nonbacterial osteitis in children: data of a German Incidence Surveillance Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25545761" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A large national cohort of French patients with chronic recurrent multifocal osteitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23071213" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pediatric chronic nonbacterial osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28461645" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment Response and Longterm Outcomes in Children with Chronic Nonbacterial Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088861" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic nonbacterial osteomyelitis in children: a retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29282260" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chronic non-bacterial osteitis from the patient perspective: a health services research through data collected from patient conferences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28686717" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Correction: Recessive coding and regulatory mutations in FBLIM1 underlie the pathogenesis of chronic recurrent multifocal osteomyelitis (CRMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16951691" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16397132" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23600784" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Clinical manifestations, response to treatment, and clinical outcome for Weimaraners with hypertrophic osteodystrophy: 53 cases (2009-2011).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24182852" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Autoinflammatory bone diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22032624" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mutation screening of the IL-1 receptor antagonist gene in chronic non-bacterial osteomyelitis of childhood and adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11973628" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chronic recurrent multifocal osteomyelitis (CRMO): evidence for a susceptibility gene located on chromosome 18q21.3-18q22.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21327433" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Predictive factors related to progression toward rheumatoid arthritis in Korean patients with undifferentiated arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10630504" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25936788" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Chronic recurrent multifocal osteomyelitis in children: nine years' experience at a statewide tertiary paediatric rheumatology referral centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28361334" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chronic Recurrent Multifocal Osteomyelitis and Related Diseases-Update on Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25061439" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Deregulation of the IL-1βaxis in chronic recurrent multifocal osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28685269" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The molecular pathophysiology of chronic non-bacterial osteomyelitis (CNO)-a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25894861" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : New discoveries in CRMO: IL-1β, the neutrophil, and the microbiome implicated in disease pathogenesis in Pstpip2-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25175678" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27000045" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15647436" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Chronic non-bacterial osteomyelitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037875" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25274309" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dietary modulation of the microbiome affects autoinflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27730289" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Unexpectedly high incidences of chronic non-bacterial as compared to bacterial osteomyelitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27318191" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pediatric Chronic Nonbacterial Osteomyelitis of the Jaw: Clinical, Radiographic, and Histopathologic Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23695372" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Chronic recurrent multifocal osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28167963" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Physicians' Perspectives on the Diagnosis and Treatment of Chronic Nonbacterial Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10643706" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evolution of chronic recurrent multifocal osteitis toward spondylarthropathy over the long term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782988" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Classification of non-bacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27059298" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Chronic nonbacterial osteomyelitis may be associated with renal disease and bisphosphonates are a good option for the majority of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333943" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical score for nonbacterial osteitis in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27263942" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hyperuricemia and tumor lysis syndrome in children with non-Hodgkin's lymphoma and acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16326415" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Tumor lysis syndrome in children with non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19335222" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Chronic recurrent multifocal osteomyelitis mimicked in childhood hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241478" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29425711" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Scurvy as a mimicker of osteomyelitis in a child with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19138427" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29250517" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Serum Interleukin-6 and CCL11/Eotaxin May Be Suitable Biomarkers for the Diagnosis of Chronic Nonbacterial Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21606238" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Chronic recurrent multifocal osteomyelitis: review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19567645" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Chronic recurrent multifocal osteomyelitis: comparison of whole-body MR imaging with radiography and correlation with clinical and laboratory data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27585682" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chronic Nonbacterial Osteomyelitis: Pathophysiological Concepts and Current Treatment Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979713" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Whole-body Magnetic Resonance Imaging in Chronic Recurrent Multifocal Osteomyelitis: Clinical Longterm Assessment May Underestimate Activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24899664" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy of pamidronate therapy in children with chronic non-bacterial osteitis: disease activity assessment by whole body magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22284608" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Evaluation of chronic recurrent multifocal osteitis in children by whole-body magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment Advances in Chronic Non-Bacterial Osteomyelitis and Other Autoinflammatory Bone Conditions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22765947" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of magnetic resonance imaging and 99mTechnetium-labelled methylene diphosphonate bone scintigraphy in the initial assessment of chronic non-bacterial osteomyelitis of childhood and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23696017" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Typical patterns of bone involvement in whole-body MRI of patients with chronic recurrent multifocal osteomyelitis (CRMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23696017" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Typical patterns of bone involvement in whole-body MRI of patients with chronic recurrent multifocal osteomyelitis (CRMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25058105" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Chronic recurrent multifocal osteomyelitis (CRMO) in children - single-centre clinical observations and experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21589819" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A thirteen year old female with primary T-cell rich B-cell lymphoma of bone masquerading as chronic recurrent multifocal osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20383509" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Whole-body MRI in the childhood form of hypophosphatasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979712" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Aggressive Therapy Reduces Disease Activity without Skeletal Damage Progression in Chronic Nonbacterial Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20433730" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20339868" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238641" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pamidronate in the treatment of childhood SAPHO syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112802" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18381777" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
